Wockhardt Limited has issued a press release regarding a clinical case involving the successful use of an investigational drug, Zidebactam/Cefepime, to treat a renal transplant patient suffering from a severe infection caused by drug-resistant bacteria. The publication highlights the challenges of antibiotic resistance in India and emphasizes the need for novel antibiotics to combat multi-drug resistant infections. The case study, published in a European journal, details how the patient, who had previously failed treatment with available antibiotics, responded positively to the investigational drug under compassionate use. This press release serves to inform stakeholders about the significant findings related to antibiotic resistance and the potential of new treatments in critical care settings.
Wockhardt Limited has informed the Exchange regarding a press release dated March 11, 2024, titled "A leading European Journal reports achallenging Clinical Case of Successful use of under-trial drug Zidebactam/Cefepime (WCK5222, ZaynichTM) to Treat Skull Bone Infection & Pneumonia caused by Extreme-drugResistant Pseudomonas in Renal Transplant Patient".